Skip to main content
Premium Trial:

Request an Annual Quote

MetriGenix, Temple University to Build Protein Chips for Heart Disease

NEW YORK, April 3 - MetriGenix and Temple University plan to develop protein chips that target cardiovascular disease, the company said today.

Under the terms of the collaboration, Temple scientists will provide MetriGenix with a selection of proteins linked to congestive heart failure culled from in-house research and general literature. MetriGenix, in turn, will use its 4D assay system to produce flow-thru biochips with antibodies to monitor these proteins. 

The agreement also calls for researchers at Temple to use the 4D system to screen some 350 archived human myocardial tissue samples with an expanded molecular target set. This part of the deal got some financial help from the National Institute of Aging, according to MetriGenix.

Financial terms of the agreement were not disclosed.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.